Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis.

Richard LeBlanc,Hira Mian,Donna Reece,Jiandong Su,Esther Masih-Khan,Michael Chu,Victor Jimenez-Zepeda,Michael Sebag,Kevin Song,Martha Louzada,Rami Kotb,Alissa Visram,Darrell White,Julie Stakiw, Antony Reiman,Muhammad Aslam, Debra Bergstrom,Rayan Kaedbey,Engin Gul,Christopher Venner

European journal of haematology（2023）

引用 0|浏览22

暂无评分

摘要

Our observations demonstrate the poor outcome of MM patients when standard regimens based on carfilzomib and/or pomalidomide are utilized directly after daratumumab-based therapy given in the relapsed setting. Novel therapies, including immune therapies, are urgently needed to improve the outcomes of these daratumumab-exposed patients.

查看译文

关键词

carfilzomib, multiple myeloma, pomalidomide, post-daratumumab, real-world data

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要